SYN Synthetic Biologics Inc

Synthetic Biologics Inc is a late-stage biotechnology company focused on developing gut microbiome therapeutics. It is also developing monoclonal antibody therapies for the treatment of pertussis.

$0.21  +0.01 (3.44%)
As of 06/30/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/26/2007
Outstanding shares:  158,437,840
Average volume:  774,971
Market cap:   $32,669,883
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.48
PS ratio:   0.00
Return on equity:   -23.53%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy